These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 24528331)

  • 1. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.
    Kubitza D; Becka M; Mück W; Krätzschmar J
    Br J Clin Pharmacol; 2014 Aug; 78(2):353-63. PubMed ID: 24528331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.
    Moore KT; Byra W; Vaidyanathan S; Natarajan J; Ariyawansa J; Salih H; Turner KC
    Br J Clin Pharmacol; 2015 Jun; 79(6):907-17. PubMed ID: 25475601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
    Graff J; von Hentig N; Misselwitz F; Kubitza D; Becka M; Breddin HK; Harder S
    J Clin Pharmacol; 2007 Nov; 47(11):1398-407. PubMed ID: 17873238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rivaroxaban-adjusted normalized ratio: use of the prothrombin time to monitor the therapeutic effect of rivaroxaban.
    Kim B; Jang S; Lee YJ; Park N; Cho YU; Park CJ
    Br J Biomed Sci; 2019 Jul; 76(3):122-128. PubMed ID: 30967043
    [No Abstract]   [Full Text] [Related]  

  • 6. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
    Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
    J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
    Siegmund HU; Burghaus R; Kubitza D; Coboeken K
    Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor.
    Kubitza D; Becka M; Roth A; Mueck W
    J Clin Pharmacol; 2013 Mar; 53(3):249-55. PubMed ID: 23381840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
    Mueck W; Eriksson BI; Bauer KA; Borris L; Dahl OE; Fisher WD; Gent M; Haas S; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
    Clin Pharmacokinet; 2008; 47(3):203-16. PubMed ID: 18307374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
    Mueck W; Lensing AW; Agnelli G; Decousus H; Prandoni P; Misselwitz F
    Clin Pharmacokinet; 2011 Oct; 50(10):675-86. PubMed ID: 21895039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.
    Kubitza D; Roth A; Becka M; Alatrach A; Halabi A; Hinrichsen H; Mueck W
    Br J Clin Pharmacol; 2013 Jul; 76(1):89-98. PubMed ID: 23294275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
    Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
    Girgis IG; Patel MR; Peters GR; Moore KT; Mahaffey KW; Nessel CC; Halperin JL; Califf RM; Fox KA; Becker RC
    J Clin Pharmacol; 2014 Aug; 54(8):917-27. PubMed ID: 24668660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.
    Arachchillage DR; Efthymiou M; Mackie IJ; Lawrie AS; Machin SJ; Cohen H
    Thromb Res; 2015 Feb; 135(2):388-93. PubMed ID: 25555316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
    Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
    Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warfarin monitoring with viscoelastic haemostatic assays, thrombin generation, coagulation factors and correlations to Owren and Quick prothrombin time.
    Nilsson CU; Strandberg K; Reinstrup P
    Scand J Clin Lab Invest; 2018 Sep; 78(5):358-364. PubMed ID: 29792060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
    Mahaffey KW; Hellkamp AS; Patel MR; Hannan KL; Schwabe K; Nessel CC; Berkowitz SD; Halperin JL; Hankey GJ; Becker RC; Piccini JP; Breithardt G; Hacke W; Singer DE; Califf RM; Fox KA
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):470-8. PubMed ID: 23759472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.